These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 11295793)

  • 1. Hemi-parkinsonism due to a midbrain arteriovenous malformation: dopamine transporter imaging.
    Goldstein S; Friedman JH; Innis R; Seibyl J; Marek K
    Mov Disord; 2001 Mar; 16(2):350-3. PubMed ID: 11295793
    [No Abstract]   [Full Text] [Related]  

  • 2. SPECT imaging of the dopamine transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction.
    Sakakibara R; Shinotoh H; Uchiyama T; Yoshiyama M; Hattori T; Yamanishi T
    J Neurol Sci; 2001 Jun; 187(1-2):55-9. PubMed ID: 11440745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in dopamine availability in the nigrostriatal and mesocortical dopaminergic systems by gait in Parkinson's disease.
    Ouchi Y; Kanno T; Okada H; Yoshikawa E; Futatsubashi M; Nobezawa S; Torizuka T; Tanaka K
    Brain; 2001 Apr; 124(Pt 4):784-92. PubMed ID: 11287377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease.
    Scherfler C; Seppi K; Donnemiller E; Goebel G; Brenneis C; Virgolini I; Wenning GK; Poewe W
    Brain; 2005 Jul; 128(Pt 7):1605-12. PubMed ID: 15817519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vulnerability of 125I-alpha-conotoxin MII binding sites to nigrostriatal damage in monkey.
    Quik M; Polonskaya Y; Kulak JM; McIntosh JM
    J Neurosci; 2001 Aug; 21(15):5494-500. PubMed ID: 11466420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positron emission tomography of striatal serotonin transporters in Parkinson disease.
    Kerenyi L; Ricaurte GA; Schretlen DJ; McCann U; Varga J; Mathews WB; Ravert HT; Dannals RF; Hilton J; Wong DF; Szabo Z
    Arch Neurol; 2003 Sep; 60(9):1223-9. PubMed ID: 12975287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study.
    Ouchi Y; Kanno T; Okada H; Yoshikawa E; Futatsubashi M; Nobezawa S; Torizuka T; Sakamoto M
    Ann Neurol; 1999 Nov; 46(5):723-31. PubMed ID: 10553989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term methamphetamine-induced decreases of [(11)C]WIN 35,428 binding in striatum are reduced by GDNF: PET studies in the vervet monkey.
    Melega WP; Lacan G; Desalles AA; Phelps ME
    Synapse; 2000 Mar; 35(4):243-9. PubMed ID: 10657033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease.
    Frost JJ; Rosier AJ; Reich SG; Smith JS; Ehlers MD; Snyder SH; Ravert HT; Dannals RF
    Ann Neurol; 1993 Sep; 34(3):423-31. PubMed ID: 8363363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism.
    Murray AM; Weihmueller FB; Marshall JF; Hurtig HI; Gottleib GL; Joyce JN
    Ann Neurol; 1995 Mar; 37(3):300-12. PubMed ID: 7695230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopaminergic activities in the human striatum: rostrocaudal gradients of uptake sites and of D1 and D2 but not of D3 receptor binding or dopamine.
    Piggott MA; Marshall EF; Thomas N; Lloyd S; Court JA; Jaros E; Costa D; Perry RH; Perry EK
    Neuroscience; 1999 May; 90(2):433-45. PubMed ID: 10215149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Objective measures for the progression of Parkinson's disease.
    Snow B
    J Neurol Neurosurg Psychiatry; 2003 Mar; 74(3):287. PubMed ID: 12588908
    [No Abstract]   [Full Text] [Related]  

  • 13. Nigral dysfunction in drug-induced parkinsonism: an 18F-dopa PET study.
    Burn DJ; Brooks DJ
    Neurology; 1993 Mar; 43(3 Pt 1):552-6. PubMed ID: 8451000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anatomic and biochemical correlates of the dopamine transporter ligand 11C-PE2I in normal and parkinsonian primates: comparison with 6-[18F]fluoro-L-dopa.
    Poyot T; Condé F; Grégoire MC; Frouin V; Coulon C; Fuseau C; Hinnen F; Dollé F; Hantraye P; Bottlaender M
    J Cereb Blood Flow Metab; 2001 Jul; 21(7):782-92. PubMed ID: 11435790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lesion of the dorsorostral midbrain sparing the nigrostriatal tract mimics axial rigidity seen in progressive supranuclear palsy.
    Lewerenz J; Zurowski B; Jenicke L; Bäumer T; Lees AJ; Münchau A
    Mov Disord; 2005 Aug; 20(8):1071-5. PubMed ID: 15838851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serotonin transporters in the midbrain of Parkinson's disease patients: a study with 123I-beta-CIT SPECT.
    Kim SE; Choi JY; Choe YS; Choi Y; Lee WY
    J Nucl Med; 2003 Jun; 44(6):870-6. PubMed ID: 12791812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progression of changes in dopamine transporter binding site density as a result of cocaine self-administration in rhesus monkeys.
    Letchworth SR; Nader MA; Smith HR; Friedman DP; Porrino LJ
    J Neurosci; 2001 Apr; 21(8):2799-807. PubMed ID: 11306632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Visualization of ischemic insult in caudate putamen with beta-CIT.
    Fujita M; Shimada S; Tohyama M; Nishimura T
    J Nucl Med; 1996 Jul; 37(7):1214-8. PubMed ID: 8965201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of neostriatal acetylcholine in the rat by dopamine and 5-hydroxytryptamine afferents.
    Butcher SH; Butcher LL; Cho AK
    Life Sci; 1976 Apr; 18(7):733-43. PubMed ID: 1263754
    [No Abstract]   [Full Text] [Related]  

  • 20. Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease.
    Rinne JO; Ruottinen H; Bergman J; Haaparanta M; Sonninen P; Solin O
    J Neurol Neurosurg Psychiatry; 1999 Dec; 67(6):737-41. PubMed ID: 10567489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.